major depressive disorder

FDA expands use of controversial J&J antidepressant
FDA expands use of controversial J&J antidepressant
Beckers Hospital Review
FDA
JNJ
Spravato
treatment-resistant depression
major depressive disorder
ketamine
Flag link:
Acadia fails in attempt to expand use of antipsychotic to treat patients with depression
Acadia fails in attempt to expand use of antipsychotic to treat patients with depression
Stat
Acadia Pharma
clinical trials
major depression
Nuplazid
major depressive disorder
antipsychotics
Flag link:
Presented with upbeat Alzheimer's agitation data, FDA sees another 'breakthrough' in Axsome's AXS-05
Presented with upbeat Alzheimer's agitation data, FDA sees another 'breakthrough' in Axsome's AXS-05
Endpoints
Axsome Therapeutics
Alzheimer's disease
AXS-05
major depressive disorder
Flag link:
Sage to run 3 new studies to save once-failed depression drug
Sage to run 3 new studies to save once-failed depression drug
Fierce Biotech
SAGE Therapeutics
SAGE-217
major depressive disorder
clinical trials
Flag link:
Here's Why Sage Therapeutics Lost 53.3% in December
Here's Why Sage Therapeutics Lost 53.3% in December
Motley Fool
SAGE Therapeutics
SAGE-217
major depressive disorder
clinical trials
Flag link:
How Big of a Deal Is Axsome Therapeutics' New Depression Drug?
How Big of a Deal Is Axsome Therapeutics' New Depression Drug?
Motley Fool
Axsome Therapeutics
AXS-05
major depressive disorder
Flag link:
3 Biotech Stocks With Big Incoming Catalysts
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
Axsome Therapeutics
AXS-05
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
major depressive disorder
Intra-Cellular Therapies
lumateperone
schizophrenia
Flag link:
Axsome’s Depression Drug Meets Phase 3 Goals, FDA Filing Planned
Axsome’s Depression Drug Meets Phase 3 Goals, FDA Filing Planned
Xconomy
Axsome Therapeutics
AXS-05
major depressive disorder
clinical trials
Flag link:
Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60%
Sage Therapeutics Depression Drug Fails in Phase 3, Shares Fall 60%
Xconomy
SAGE Therapeutics
clinical trials
SAGE-217
major depressive disorder
Flag link:
FDA tags psilocybin drug as clinical depression Breakthrough Therapy
FDA tags psilocybin drug as clinical depression Breakthrough Therapy
Pharmaforum
FDA
psilocybin
major depressive disorder
Usona
PSIL201
Flag link:
VistaGen fails phase 2 depression trial, sparking stock rout
VistaGen fails phase 2 depression trial, sparking stock rout
Fierce Biotech
VistaGen
AV-101
major depressive disorder
clinical trials
Flag link:
Upcoming events – Sage targets depression and Biogen aims for lupus
Upcoming events – Sage targets depression and Biogen aims for lupus
EP Vantage
SAGE Therapeutics
SAGE-217
major depressive disorder
Biogen
BIIB059
lupus
Flag link:
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
FDA Overlooked Red Flags In Drugmaker’s Testing of New Depression Medicine
KHN
FDA
Janssen
Spravato
esketamine
major depressive disorder
Flag link:
Otsuka, Click to develop digital therapeutics for MDD
Otsuka, Click to develop digital therapeutics for MDD
Pharmaceutical Business Review
Otsuka
Click Therapeutics
digital therapeutics
major depressive disorder
Flag link:
More data could be key for Alkermes after FDA panel vote
More data could be key for Alkermes after FDA panel vote
BioCentury
Alkermes
ALKS 5461
major depressive disorder
FDA
Flag link:
Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
Alkermes Depression Drug Faces Long Odds After FDA Advisors Say No
Xconomy
Alkermes
FDA
advisory panels
ALKS-5461
major depressive disorder
Flag link:
FDA Blasts Data, Trial Design For Alkermes Depression Drug
FDA Blasts Data, Trial Design For Alkermes Depression Drug
Xconomy
FDA
Alkermes
ALKS 5461
clinical trials
major depressive disorder
Flag link:
Janssen, Lundbeck and Takeda Raise Issues With FDA Draft Guidance on MDD Drugs
Janssen, Lundbeck and Takeda Raise Issues With FDA Draft Guidance on MDD Drugs
RAPS.org
FDA
JNJ
Janssen
Lundbeck
Takeda
major depressive disorder
drug development
Flag link:
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
CP Wire
SAGE Therapeutics
FDA
breakthrough status
SAGE-217
major depressive disorder
postpartum depression
Flag link:
Sage to Expedite Development of SAGE-217 in Major Depressive Disorder and Postpartum Depression
SAGE Therapeutics
SAGE-217
major depressive disorder
postpartum depression
Flag link:

Pages